- Fed Sanguine About US Recovery, Worried on Jobs
- In Time for Holidays: More Gloom and Doom on Economy
- Turkey Day 101: How Well Do You Know Your Bird?
- Facebook Creates Dual-Class Stock Structure
- US Home Prices Up 5th Month, 2nd Straight Quarter
- Holiday Guide to This Season's Smartphones
- Six Ways to Boost Your Income in a Big Way
- Buyers Look for Bargains at Luxury Condo Auction
- Ron Paul's Plan to Audit Fed a 'Serious Attack': Mishkin
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- NBA D-League On The Rise
- 3D's Tipping Point and Your Living Room
- On Twitter, Beware False Prophets
- My 2010 Home Price Outlook: UBS Analyst
- Why Are Options Piling into Dollar Tree?
- Novartis 'Cells' Its Flu Vaccine Technology
- Silicon Valley and Hollywood Now Fast Friends
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- GM's Agreement to Sell Saab To Swedish Firm Falls Apart
- Buyers Look For Bargains At Luxury Condo Auction
- US Home Prices Up 5th Month, 2nd Straight Quarter
- FDIC Fund Falls into The Red, Bair Urges Lending
- Just In Time for Holidays: More Gloom and Doom on Economy
- NBA D-League On The Rise
- Behind The Scenes With Warren Buffett
- 10 Holiday Cocktail Recipes from Top Mixologists
- CA "More Profitable" After Saving Energy: CEO
Text Size 
A new study shows that a diabetes treatment awaiting FDA approval may also work as a weight loss drug.
 |
AP |
Obese patients who took various doses of the one-a-day injectable Victoza from Novo Nordisk [NVO
Loading...
()
] lost between 10 and 14 pounds.
That compares to nine pounds shed by clinical trial participants who took the prescription diet pill Xenical from Roche [RHHBY
Loading...
()
], which is also sold without a prescription by GlaxoSmithKline [GSK
Loading...
()
] in lower doses under the brand name Alli. The results are in the new issue of the British medical journal "The Lancet."
In addition, three out of four patients who got Victoza lost at least 5 percent of their body weight. And it cut the prevalence of so-called prediabetes by 84-96 percent.
The FDA is deciding whether to approve Victoza as a diabetes treatment. It would compete with a similar drug Byetta from Eli Lilly [LLY
Loading...
()
] and Amylin Pharmaceuticals [AMLN
Loading...
()
].
Researchers say longer-term studies need to be done on Victoza in the obese population, but this study shows its potential as an "important" treatment for obese prediabetics.
A Novo spokesperson did not provide a comment on the study.
Print
Email
- Remember when auto shows were major events where new models could generate buzz?
- CNBC’s Mike Huckman visits a cutting-edge plant to see how the flu vaccine of the future is being made.
- A new McDonald's in Manhattan is the nation's first to sport a sleek, chic interior imported from stores in London and Paris.
- Italians were outraged by a minister's comments that lunchbreaks are bad for waistlines and the economy.
- Playboy will outsource its publishing operations in a bid to become profitable again.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes